Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,367 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose Control Clear all
Completed Phase 4 Interventional Results available

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

NCT02917031
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Heart Failure
Interventions
Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Torrance, California • Upland, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 25, 2026, 8:02 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Metabolic Wellness and CGM

NCT06790472
View directory record Official record
Conditions
Cardiometabolic Risk Factors
Interventions
Online Lifestyle Intervention, Continuous Glucose Monitoring
Behavioral · Device
Lead sponsor
David Kerr
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

NCT03965130
View directory record Official record
Conditions
Healthy Participants
Interventions
Glucagon, Control Study
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 25, 2026, 8:02 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers

NCT05662865
View directory record Official record
Conditions
Ketones, Metabolism
Interventions
SGLT2 inhibitor, Controlled, Adaptive Study Diet
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 25, 2026, 8:02 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

NCT04677829
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
PNT001, %5 dextrose for infusion
Biological
Lead sponsor
Pinteon Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes

NCT04443153
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Personalized Feedback, Decision Support System, Sensor Augmented Mode
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 4 Interventional Results available

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 25, 2026, 8:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes

NCT06548828
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy, Non-nutritive Sweeteners Consumption in Pregnancy and/or Lactation
Interventions
NNS Restriction Intervention, Control Intervention
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 8:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

NCT01465165
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Paul Carlson
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

NCT04540536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Noncompliance, Patient
Interventions
Continuous Glucose Monitoring, Secure texting
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy

NCT05430204
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Group 1: one-hour GCT, Group 2: CGM placement
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
1,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Not applicable Interventional

Valued EpiGenetic Glycemic ImprovEments Through Weight Loss

NCT02869659
View directory record Official record
Conditions
Obesity, Pre-diabetes
Interventions
Weight Loss Group, Delayed Weight Loss
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

NCT00551564
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone maleate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6

NCT04084171
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Device
Lead sponsor
University of Virginia
Other
Eligibility
2 Years to 6 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 25, 2026, 8:02 PM EDT
Withdrawn Phase 4 Interventional

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

NCT03190798
View directory record Official record
Conditions
Type2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
Canagliflozin 300mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 25, 2026, 8:02 PM EDT
Recruiting Early Phase 1 Interventional

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

NCT05041491
View directory record Official record
Conditions
Pre-diabetes
Interventions
BREAK, ONE
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 25, 2026, 8:02 PM EDT
Completed No phase listed Observational

Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa

NCT04708015
View directory record Official record
Conditions
Glycogen Storage Disease Type IA
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 4 Interventional

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

NCT00878878
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Elliott, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 25, 2026, 8:02 PM EDT
Completed No phase listed Observational

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

NCT00803920
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

NCT04595370
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease
Interventions
AZD9977, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 130 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

NCT00995670
View directory record Official record
Conditions
Hyperglycemia
Interventions
5% dextrose, Vitamin C, Simvastatin, Sevoflurane
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 25, 2026, 8:02 PM EDT
Completed Phase 4 Interventional

Continuous Glucose Monitoring and Preterm Infants

NCT02583776
View directory record Official record
Conditions
Infant, Very Low Birth Weight, Neonatal Hypoglycemia
Interventions
Unblinded - CGM, Blinded - CGM
Device
Lead sponsor
University Hospital Padova
Other
Eligibility
2 Hours to 2 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 25, 2026, 8:02 PM EDT